Efficacy of combined antihypertension and cholesterol lowering treatment on atherosclerosis in patients with essential hypertension
MIAO Huining1, JIA Xinwei2, ZHANG Hong2, SONG Xuena3, CAO Yafeng4, LI Dandan4, LIU Chunxia4, YAN Zhenfeng4, LIU Qian5, WANG Yushui5
1. Department of Business, Baoding Local Blood Center, Hebei Province, Baoding 071051, China; 2. Department of Cardiology, Affillated Hospital of Hebei University, Baoding 071000, China; 3. Department of Cardiology, Baoding First Center Hospital, Hebei Province, Baoding 071000, China; 4. Department of Cardiology, Mancheng People’s Hospital, Hebei Province, Mancheng 072150, China; 5. Department of Cardiology, Gaobeidian People’s Hospital, Hebei Province, Gaobeidian 074000, China
Abstract：Objective To evaluate the efficacy of combined antihypertension and cholesterol lowering treatment on atherosclerosis in patients with essential hypertension.Methods 120 patients with high blood pressure were recruited from June 2012 to June 2013 in the Affillated Hospital of Hebei University. By carotid ultrasound examination, all patients showed carotid IMT thickening (IMT value≥0.9 mm), 120 patients were randomly divided into 2 groups by the double blind method. Control group consisted of 60 patients in health education, on regimen of low salt, low fat diet, quitting smoking and smoking were given benazepril orally (10 mg/d, QD). Study group (60 cases, on the basis of the medicament in control group, were given rosuva statin orally (10 mg/d, QN). Treatments lasted for 8 weeks, the blood pressure, IMT and blood fat in the two groups were recorded before and after treatment, and compared between the two groups, and statistical analysis was conducted. Results Before the treatment, the control group showed IMT values (1.05±0.32)mm, the study group (1.06±0.29) mm; after treatment, the control group showed IMT (0.89±0.17) mm, the treatment group (0.58±0.19) mm. Compared with before treatment, IMT were reduced after treatment in both groups, differences were statistically significant (P<0.05). Blood pressure significantly decreased after treatment, with statistically significant difference(P<0.05), but comparison between the two groups had no statistical difference. Blood lipid levels in the control group before and after treatment were not statistically different (P<0.05), the study group showed compared with before treatment, the blood lipid level declined obviously, with statistically significant difference (P<0.05). Compared with the control group after treatment, the study group showed lipid levels dropped significantly after treatment, with statistically significant difference(P<0.05). Conclusions Benazeprilin combined with rosuvastatin in patients with hypertension has good reversal effect on carotid IMT, which can delay the progress of atherosclerosis.
缪惠宁, 贾新未, 张虹, 宋雪娜, 曹亚峰, 李丹丹, 刘春霞, 闫振锋, 刘倩, 王雨水. 降压和调脂联合治疗对高血压动脉粥样硬化的影响[J]. 武警医学, 2015, 26(3): 266-268.
MIAO Huining, JIA Xinwei, ZHANG Hong, SONG Xuena, CAO Yafeng, LI Dandan, LIU Chunxia, YAN Zhenfeng, LIU Qian, WANG Yushui. Efficacy of combined antihypertension and cholesterol lowering treatment on atherosclerosis in patients with essential hypertension. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(3): 266-268.
Polak J F,Pencina M J,Karol A M,et al. Associations of Carotidaltery Intima-media Thickness(IMT) with risk factors and prevalent cardiovascular disease: comparison of mean common carotidartery IMT with maximum internal carotid artery IMT[J].Ultrasound Med,2010,29(12):1759-1768.
Nissen S E, Nicholls S J, Sipahi I, et al. Effect of very high-intensity station therapy on regression of coronary atherosclerosis: the ASTEROID trial[J]. JAMA, 2006, 295: 1556-1565.
Polak J F,Pencina M J,Karol A M,et al. Associations of Carotidaltery Intima-media Thickness(IMT) with risk factors and prevalent cardiovascular disease: comparison of mean common carotidartery IMT with maximum internal carotid artery IMT[J].Ultrasound Med,2010,29(12):1759-1768.
Nissen S E, Nicholls S J, Sipahi I, et al. Effect of very high-intensity station therapy on regression of coronary atherosclerosis: the ASTEROID trial[J]. JAMA, 2006, 295: 1556-1565.
2015, Vol. 26 
